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Causal association of circulating cholesterol levels
with dementia: a mendelian randomization
meta-analysis
Xiaoyu Zhang1, Qiuyue Tian1, Di Liu1, Tao Geng2, Xizhu Xu3, Siqi Ge4, Deqiang Zheng1, Lijuan Wu1, Manshu Song1,
Haifeng Hou3, Wei Wang 5 and Youxin Wang 1
Abstract
Prospective studies have shown that abnormally circulating cholesterol is associated with the risk of dementia.
However, whether the association is causal or not remains unclear. We attempt to infer the causal association in a MR
meta-analysis by using ApoE gene polymorphisms as instrument variables. Studies with dementia risk (27 studies) or
circulating lipid levels (7 studies) were included, with totally 3136 dementia patients and 3103 healthy controls. The
analyses showed that carriers of ε2 allele significantly were of decreased risk of AD (OR= 0.70; 95% CI: 0.58–0.84; P <
0.01), whereas carriers of ε4 allele were of increased risk of AD (OR= 3.62; 95% CI: 3.03–4.32; P < 0.05), compared to
these of ε3 allele. Circulating TC was significantly reduced in carriers of ε2 allele (WMD=− 0.29 mmol/L; 95% CI: −0.54
to −0.03; P < 0.05) and increased in carriers of ε4 allele (WMD= 0.42 mmol/l; 95% CI: 0.001–0.84; P < 0.05). In addition,
carriers of ε4 allele had reduction in circulating HDL-C (WMD=− 0.04 mmol/L; 95% CI:− 0.07 to −0.001; P < 0.05). In
comparing allele ε2 with ε3, the predicted OR of having AD for 1 mg/dL increment in circulating TC was 0.97 (95% CI:
0.86–0.98; P < 0.05). Comparing allele ε4 with ε3, the predicted OR for a 1 mg/dL increment in TC was 1.08 (95% CI:
1.05–17.58; P < 0.05), and reduction in HDL-C was 2.30 (95% CI: 1.51–43.99; P < 0.05). Our findings demonstrate that
high circulating TC and reduced HDL-C levels might be potential risk factors of the development of AD.
Introduction
Dementia is a syndrome caused by a variety of brain
illnesses that have adverse impact on memory, thinking,
behavior and the ability to perform daily activities. Alz-
heimer’s disease (AD) and vascular dementia (VaD)
account for more than 90% of the dementia cases1. The
number of dementia patients currently is 47 million and
estimated to 75 million by 2030 in globe2. The increasing
burden of dementia emphasizes the necessity to identify
risk factors underlying prevention of dementia.
Some prospective studies have revealed that circulating
lipid abnormalities are independent indicators of the
development of dementia3–7. In addition, dyslipidemia is a
risk factor for vascular diseases, which is clearly associated
with VaD and AD8. High total cholesterol (TC) levels
were found to be positively associated with the risk of AD
in a dose–response manner9, while higher high-density
lipoprotein cholesterol (HDL-C) (>55mg/dL) resulted in
decreased risk of AD10. However, confounding factors
such as age and sex may also explain some of the observed
associations, suggesting that the value is susceptible to
confounding.
Differences in the amino acid sequence of apolipopro-
tein E (ApoE) are major determinants of plasma choles-
terol levels within a population level. ApoE has a key role
in the clearance of cholesterol from plasma11. It has been
estimated that nearly 60% of circulating cholesterol
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variation is under genetic control and thereout 14% var-
iation is ascribed to ApoE genetic defects12. The synthesis
of ApoE is controlled by three independent alleles such as
ε2, ε3 and ε4, corresponding to 6 ApoE genotypes (ε2ε2,
ε3ε2, ε4ε2, ε3ε3, ε4ε3 and ε4ε4)13. Genotypes ε4/ε4 and
ε4/ε3 are associated with high cholesterol concentration
in blood14–17. In addition, polymorphisms of the ApoE
gene have been studied extensively in the context of a
variety of clinical endpoints such as hypercholester-
olemia18,19, ischemic heart disease20,21, stroke22 and
hypertension23,24.
In the absence of trials, genetic studies can be used to
help evaluate causality. This approach is known as Men-
delian randomization (MR) which can be used to assess
gene-related risk factors for causal associations with
clinical outcomes. MR analyses are based on Mendel’s
observation that inheritance of one trait should be inde-
pendent of the inheritance of other traits25. To test this
hypothesis and provide an unbiased estimation of the
causality, MR meta-analysis was used to assess the caus-
ality between circulating lipid profiles and the risk of
dementia.
Materials and Methods
The present meta-analysis was undertaken in accor-
dance with the guidelines formulated in the Preferred
Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) statement26.
Search strategy for qualified studies
To identify all relevant articles that addressed the
associations of ApoE gene ε2/ε3/ε4 polymorphism with
dementia or circulating lipid changes, we systematically
searched PubMed and the Excerpta Medica database
(EMBASE) for literature in the English language. For the
research strategy, logic based on specific descriptors was
adopted (English language) in combination with Boolean
operators (and/or), with the aid of parentheses to define
intercalation within the same logic and the quotation
marks to identify the compound words. The search was
conducted using the following search terms: (APOE,
“Apolipoprotein E” or “apo-E”) and (polymorphism, allele,
variant, variation, genotype, mutation, SNP or isoforms)
and (dementia, “Alzheimer*” or “vascular dementia”) and
(“lipid profile”, “total cholesterol”, triglyceride, triacylgly-
cerol, “high-density lipoprotein cholesterol”, “low-density
lipoprotein cholesterol”, TC, “HDL-C”, “LDL-C” or TG).
All selected articles were written in English and published
before 20 June 2019. In addition, we manually scrutinized
the reference list of eligible literature.
The titles and abstracts of all retrieved articles were read
independently by two authors (Xiaoyu Zhang and Qiuyue
Tian). For articles that could not be ascertained, the full
text and supplementary data were reviewed. The process
was conducted independently by the two authors. The
discrepancy was adjudicated by a discussion with the third
author (Di Liu).
Inclusion and exclusion criteria
The literatures that met the following criteria were
included in the meta-analysis: 1) detailed allele or geno-
type counts of ApoE ε2/ε3/ε4 gene polymorphism should
be available between dementia patients and controls in
case-control studies (including nested case-control stu-
dies); 2) the mean or median values (standard deviations)
on TC, HDL-C, LDL-C and triglyceride (TG) levels were
found across ApoE gene ε2/ε3/ε4 alleles or genotypes in
case-control (including nested case-control) or cohort
studies.
The exclusion criteria were as follows: 1) studies that
examined the progression, severity or response to treat-
ment of dementia in association with ApoE gene ε2/ε3/ε4
polymorphism or a lack of healthy controls; 2) case
reports or series, editorials, narrative or systematic
reviews, conference abstracts or proceedings and non-
English articles.
Literature quality assessment
The Newcastle–Ottawa Scale was used to assess the
methodological quality of the included studies27. For case-
control studies, this comprised the determination of (1)
adequate case definition, (2) representativeness of cases,
(3) selection of control, (4) definition of control, (5)
comparability of case and control groups, (6) exposure, (7)
whether there were identical exposure methods for cases
and controls, and (8) non-response rate. For cohort stu-
dies, this comprised the determination of (1) representa-
tiveness of the exposed cohort, (2) selection of the
unexposed cohort, (3) exposure, (4) whether the study
subjects had an ending event that occurred before the
study began, (5) comparability of the cohorts, (6) eva-
luation of the ending event, (7) whether follow-up was
sufficient, and (8) integrity of follow-up examinations.
Each item that met one of the above-mentioned criteria
was represented by ∗, and each ∗ was equivalent to 1
point, giving a potential total of 9 points. Higher scores
indicated higher quality studies. Moreover, studies with a
score of 6 points and above were included in the present
meta-analysis.
Extracted information
Data including the first author’s last name, publication
year, ethnicity, dementia subtype, sample size, allele
counts of ApoE gene ε2/ε3/ε4 polymorphisms between
dementia patients and controls, the mean or median
(standard deviation) values of TC, TG, HDL-C and LDL-
C levels across ApoE gene ε2/ε3/ε4 carriers were extracted
independently from each qualified study by two
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investigators (Xiaoyu Zhang and Qiuyue Tian). The units
of circulating TG, TC, HDL-C and LDL-C were con-
sistently standardized to millimole per liter (mmol/L).
The following data collection and article quality were
assessed in duplicate.
Statistical analyses
Data management and statistical analyses were per-
formed with Stata software (StataCorp, TX, USA, version
12.0 for Windows). The odds ratios (ORs) and 95% con-
fidence intervals (CIs) were calculated to express the
distributional differences of alleles of ApoE gene ε2/ε3/ε4
polymorphism between patients with dementia and the
controls. Weighted mean differences (WMDs) and 95%
CIs were calculated to compare the changes in circulating
levels of TC, TG, HDL-C and LDL-C across allele carriers.
In this meta-based MR analysis, if the I2 values were <50%,
then the fixed effects model was selected to calculate the
pooled ORs and 95% CI28. Otherwise, a random effects model
was applied to combine effect-size estimates. Predetermined
subgroup analyses were undertaken prior in terms of dementia
subtype (AD and VaD), sample size, ethnicity or gender. The
probability of publication bias was determined visually by
Begg’s funnel plot and Egger’s regression asymmetry test.
Under the assumptions of MR, we calculated the risk
prediction as a ratio of the coefficient for the association
between ApoE gene ε2/ε3/ε4 polymorphism and dementia
risk to that of the relationship between the polymorphism
and circulating lipid changes. Statistical significance was
considered when a two-tailed P value was less than 0.05.
Results
Eligibility criteria
The flow chart of the selection process was shown in
Supplementary Fig. S1. For the association between ApoE
gene polymorphism ε2/ε3/ε4 and dementia, there were
27 studies with 3136 dementia patients and 3103 healthy
controls29–41. For the association between ApoE gene ε2/
ε3/ε4 polymorphism and circulating cholesterol, five
studies addressed HDL-C35,42–45, five studies addressed
LDL-C35,42–45, seven studies addressed TG35,42–47 and six
studies addressed TC35,42–46, were included.
Association of the ApoE gene alleles with dementia
Considering the limited numbers of ApoE genotypes,
only allelic comparisons (ε2 versus ε3, and ε4 versus ε3)
were computed. As shown in Fig. 1, carriers of ε2 allele
were of a significant decrease risk for dementia (OR= 0.69;
Fig. 1 Overall comparisons of ApoE gene ε2 versus ε3 in association with dementia risk. Forest plots of the dementia risk associated with the
ApoE gene ε2/ε3/ε4 alleles for ε2 vs. ε3 in all study populations.
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95% CI: 0.59 to 0.81; P < 0.01) compared to these of ε3
allele, with a low probability of publication bias as
reflected by the suggestive symmetry of the funnel plot
(Supplementary Fig. S2) and the Egger’s test (P= 0.364).
There was no evidence of heterogeneity for the compar-
ison of ε2 with ε3 (I2= 8.30%). In contrast, the ε4 allele
was significantly associated with a 3.06-fold (OR= 3.06;
95% CI: 2.54–3.68; P < 0.01; Fig. 2) increased risk of
developing dementia compared with the ε3 allele,
accompanied by moderate heterogeneity (I2= 55.10%; P
< 0.01; Supplementary Fig. S3). In addition, there was no
apparent publication bias (Egger’s test: P= 0.131), which
improved the strength of this association.
Stratified comparisons for dementia risk
In an attempt to examine the potential sources of het-
erogeneity between different subgroups, several subgroup
analyses were conducted according to the dementia type,
sample size, ethnicity or gender (Table 1).
The summary effect estimates in stratified analyses were
similar in meta-analysis including studies with sample size
≥200 (OR= 0.68, 95% CI: 0.56–0.85; P < 0.05) and sample
size <200 (OR= 0.70, 95% CI: 0.49–0.99; P < 0.05) across the
comparison of ε2 vs. ε3. In addition, the summary effect
estimates were also comparable in meta-analysis including
studies with sample size ≥200 (OR= 3.05, 95% CI: 2.54–6.67;
P < 0.01) and sample size <200 (OR= 3.25, 95% CI:
2.19–4.83; P < 0.01) across the comparison of ε4 vs. ε3. In the
subgroup analyses by dementia subtypes, the association of
the ApoE gene with the risk of AD (OR= 3.62; 95% CI:
3.03–4.32; P < 0.01) was stronger across the comparison of ε4
vs. ε3. Carriers with the ε2 allele had a significant decreased
risk in patients with AD (OR= 0.70; 95% CI: 0.58–0.84; P <
0.01) compared to these with the ε3 allele.
In terms of AD, carriers with the ε4 allele were of increased
risk in Caucasian (OR= 3.53, 95% CI: 2.62–4.78; P < 0.01),
Asian (OR= 4.76, 95% CI: 3.39–6.69; P < 0.01), Latinos (OR
= 2.93, 95% CI: 1.90–4.52; P < 0.01) and North America (OR
= 3.45, 95% CI: 2.49–4.78; P < 0.01), compared to carriers
with the ε3 allele. There were consistently significant asso-
ciations for the comparison of ε2 versus ε3 in the male (OR
= 0.76; 95% CI: 0.64–0.92; P < 0.01) and female (OR= 0.74;
95% CI: 0.64–0.86; P < 0.01) in term of AD.
Association of the ApoE gene alleles with circulating
cholesterols levels
In the view of limited data on ApoE genotypes, mean
lipid changes were only compared in ε2 vs. ε3 and ε4 vs. ε3.
Fig. 2 Overall comparisons of ApoE gene ε4 versus ε3 in association with dementia risk. Forest plots of the dementia risk associated with the
ApoE gene ε2/ε3/ε4 alleles for ε4 vs. ε3 in all study populations.
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Figures 3 and 4 present the overall analyses of the ApoE
gene ε2/ε3/ε4 polymorphism with circulating levels of TC,
HDL-C, LDL-C, and TG under ε2 vs. ε3 and ε4 vs. ε3
comparisons. Carriers of ε2 allele had a significant
reduction in circulating TC (WMD=− 0.29 mmol/L;
95% CI: −0.54 to −0.03; P < 0.05; Fig. 3) when compared
to ε3 allele, with the moderate evidence of heterogeneity
(I2= 50%). In addition, carriers of the ε4 allele had a
significant reduction in circulating HDL-C (WMD=
−0.04 mmol/L; 95% CI:−0.08 to −0.001; P < 0.05) with-
out heterogeneity (I2= 0.00%), compared to carriers of
the ε3 allele. As expected, higher circulating TC was
observed in subjects with the ε4 allele (WMD=
0.42 mmol/l; 95% CI: 0.001–0.84; P < 0.05; Fig. 4) com-
pared to the ε3 allele carriers, with a significant hetero-
geneity (I2= 91.70%).
Causal prediction of circulating lipids for dementia
According to the requirements of MR approach, the
predicted OR of having AD for 1mg/dL increment in cir-
culating TC was 0.97 (95% CI: 0.86–0.98; P < 0.05) for the
comparison of allele ε2 with ε3. In comparing allele ε4 with
ε3, the predicted OR for a 1mg/dL increment in TC was
1.08 (95% CI: 1.05–17.58; P < 0.05), while the predicted OR
for a 1mg/dL reduction in HDL-C was 2.30 (95% CI:
1.51–43.99; P < 0.05). This estimate was significant at a
significance level of 5%, and the null hypothesis value of 1
was not included in the estimated 95% CI for the associa-
tion of circulating cholesterol level and risk of dementia.
Discussion
In this MR meta-analysis, ApoE gene polymorphism was
utilized as an instrumental variable to evaluate the
potential causal relation between circulating cholesterol
and the risk of dementia. To the best of our knowledge,
this is the first meta-analysis to evaluate the relationship
from the perspective of the MR approach.
Cholesterol in the pathogenesis of AD remains con-
troversial48. The lipid-AD associations are progressively
stronger with increasing pathological certainty of an AD
diagnosis. These relationships were still significant after
adjustment for the ApoE genotype and for other known
risk factors3. In addition, it is still unclear that this asso-
ciation is causal or confouder, because of the involvement
of many confounding factors including age, BMI and
genetic background, as well as the complex biological
effects of circulating lipid levels. Therefore, the MR
approach is used to assess the causal relation of circu-
lating cholesterol levels with dementia risk.
Some evidence supported a close relation between ApoE
genetic alterations and the circulating HDL-C and TC
profiles in the meta-analyses24,49–51, which revealed that
the ApoE gene ε4 allele was significantly associated with
reduced circulating HDL-C and increased circulating TC
levels. Previous MR meta-analyses have assessed the
association between genetically circulating cholesterol
levels and other diseases including cancer and hyperten-
sion. Yang et al. indicated that the predicted odds of
overall cancer for a 1 mg/dL reduction in circulating
Table 1 Subgroup analyses of the ApoE gene ε2/ε3/ε4 polymorphism with dementia risk.
ε2 vs. ε3 ε4 vs. ε3
Subgroup Studies, n OR 95% CI P I2 OR 95% CI P I2
Dementia type
AD 23 0.70 0.58–0.84 <0.01 13.10% 3.62 3.03–4.32 <0.01 32.40%
VaD 3 0.44 0.18–1.07 0.07 20.6% 1.32 0.81–2.13 0.27 0.00%
Total sample size
<200 19 0.70 0.49–0.99 <0.05 13.10% 3.25 2.19–4.83 <0.01 66.10%
≥200 14 0.68 0.56–0.85 <0.05 9.70% 3.05 2.54–3.67 <0.01 54.40%
Ethnicity in AD patients
Caucasian 12 0.65 0.43–0.96 <0.05 36.40% 3.53 2.62–4.78 <0.01 56.90%
Asian 7 0.80 0.43–1.51 0.50 19.30% 4.76 3.39–6.69 <0.01 0.00%
Latinos 1 0.71 0.30–1.67 0.43 0.00% 2.93 1.90–4.52 <0.01 0.00%
North America 3 0.59 0.32–1.07 0.08 0.00% 3.45 2.49–4.78 <0.01 0.00%
Gender in AD patients
Male 1 0.76 0.64–0.92 <0.01 100% 1.00 0.92–1.10 0.90 100%
Female 1 0.74 0.64–0.86 <0.01 100% 1.00 0.95–1.13 0.38 100%
Bold values were statistically significant differences for subgroup analyses (P < 0.05).
Zhang et al. Translational Psychiatry          (2020) 10:145 Page 5 of 8
HDL-C was 1.1452. Another study showed that a 1 mmol/
L increment in TC corresponded to a 4.58-times higher
likelihood of developing hypertension, and the same
increase in LDL-C corresponded to a 3.97-times higher
likelihood24. Because genotypes are invariant over time
and can exert an effect on circulating cholesterol levels
over a lifetime.
As for the molecular mechanisms, there has been
increasing evidence in basic medical research. Umeda et al.
observed that hypercholesterolemia accelerates the intra-
neuronal accumulation of Aβ oligomers and subsequent
synapse loss, thus resulting in memory impairment in AD
mouse models53. Chen et al. found that increased levels of
cholesterol affected the function and structure of endoly-
sosomes, leading to the deposition of Aβ and phosphory-
lated tau protein in the brain of AD rabbits54. A recent
study also demonstrated that high cholesterol and 27-
hydroxycholesterol levels affect memory consolidation in
experimental studies, suggesting that this cholesterol
metabolite could link peripheral cholesterol to AD patho-
genesis55. In a meta-analysis, the use of statins was sig-
nificantly associated with a reduced risk of all-caused
dementia (adjusted RR (aRR)= 0.849, 95% CI: 0.787–0.916)
and AD (aRR = 0.719, 95% CI: 0.576 to 0.899)56. Another
meta-analysis indicated that the use of statins might benefit
all AD subjects (HR= 0.80; 95% CI: 0.68–0.95) and may be
most beneficial in subjects with an ApoE ε4/4 genotype57.
Together, these studies strongly suggest that increased
levels of circulating cholesterol play an important role in the
pathogenesis of AD. Consequently, these studies suggested
that increased levels of circulating cholesterol might play a
causal role in the pathogenesis of AD.
Despite the strengths of this meta-analysis, some pos-
sible limitations should be acknowledged. Firstly, because
we retrieved published literatures in English, selective
publication bias could not be ruled out completely. Sec-
ondly, we only focused on the ApoE gene ε2/ε3/ε4 poly-
morphism as well as did not cover other candidate genes
or polymorphisms in this gene, which might restrict the
statistical power. Thirdly, the cholesterol levels were
measured only once for almost all eligible studies which
could not reflect the long-term cholesterol profiles in the
development of dementia. Fourthly, this meta-analysis
was conducted with the use of summarized data rather
Fig. 3 Overall circulating cholesterol levels for the comparisons of ApoE gene ε2 versus ε3. Forest plots of circulating cholesterol levels
associated with the ApoE gene ε2/ε3/ε4 alleles for ε2 vs. ε3 from the available studies.
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than individual participant data, with age-stratified,
homozygous and heterozygous genotypes analyses una-
vailable. Fifthly, an essential requirement of MR was that a
pleiotropic effect of the ApoE gene ε2/ε3/ε4 polymorph-
ism was not be calculated and might beyond the capability
to eliminate this effect in this meta-analysis. Therefore, a
solid conclusion could not be produced from this meta-
analysis which should be treated cautiously, until large,
well-designed, prospective studies confirm our findings.
In conclusion, our results indicate that reduced circu-
lating HDL-C and increased TC levels may be potential
risk factors for dementia. Our findings in this study are
promising for future practical applications.
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